PROGNOSTIC VALUE of SERUM NEUROFILAMENT LIGHT CHAIN for DISEASE ACTIVITY in PATIENTS with RELAPSING MULTIPLE SCLEROSIS: RESULTS from SUBGROUP ANALYSIS BASED on BODY MASS INDEX and AGE from the PHASE 3 ASCLEPIOS I/II TRIALS

Authors
Category Primary study
Conference54th Annual Conference of the Italian Society of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: a8a031ce0a6e999b1c6fa51036aac36f6c361f88
First added on: Jan 10, 2026